Mymetics Corporation

OTC: MYMX    
Share price (2/16/24): $0.01    
Market cap (2/16/24): $1.516 thousand
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K/A 4 pages Confidential Disclosure Agreement
12/34/56
EX-10.1
from 8-K 8 pages Research Agreement
12/34/56
EX-10
from 8-K 7 pages Agreement Between Mymetics S.A. and Breslin AG
12/34/56
EX-10.1
from 8-K 22 pages Master Services Agreement
12/34/56
EX-10.1
from 8-K/A 43 pages Exclusive License and Collaboration Agreement
12/34/56
EX-10.1
from 8-K 43 pages Exclusive License and Collaboration Agreement
12/34/56
EX-10.1
from 8-K 5 pages Strictly Private & Confidential Amendment Dated March 28, 2013 to the Share Purchase Agreement Dated as of March 5, 2009 and the Amendments Thereto Dated 19 April 2012, 21 September 2012, 31 October 2012, 1 November 2012, 28 November 2012 and 28 January 2013 Between
12/34/56
EX-10.1
from 8-K 15 pages Second Amended and Restated Executive Employment Agreement
12/34/56
EX-10.65
from 10-K 4 pages Mymetics Corporaton Route De La Corniche 4 Ch-1066 Epalinges, Switzerland July 30, 2010
12/34/56
EX-10.64
from 10-K 3 pages Material contract
12/34/56
EX-10.64
from 10-K/A 5 pages Material contract
12/34/56
EX-10.2
from 8-K 8 pages Consulting Agreement
12/34/56
EX-10.1
from 8-K 7 pages Mymetics Corporaton Route De La Corniche 4 Ch-1066 Epalinges, Switzerland July 30, 2010
12/34/56
EX-10.1
from 8-K 58 pages ’’’’’’’ Share Purchase Agreement Dated as of March 5, 2009 Relating to the Shares of Bestewil Holding B.V. -1
12/34/56
EX-10.1
from 8-K 9 pages Umbrella Agreement
12/34/56
EX-10.1
from 10-Q ~10 pages Material contract
12/34/56
EX-10.1
from 8-K 3 pages Mymetics Corporation Acquires Preventive Malaria Vaccine From Pevion Biotech AG (Switzerland) Successful Phase I and II Clinical Trials in Switzerland and the Uk Results Praised by an Eminent Member of the Pasteur Institute and of the Malaria Board of the Bill and Melinda Gates Foundation
12/34/56
EX-10.1
from 10-Q ~20 pages Material contract
12/34/56
EX-10
from SC 13D/A 1 page Mass Financial Corp
12/34/56
EX-10.1
from 8-K 69 pages Next Generation Hiv-1 Immunogen Inducing Broadly Reactive Neutralizing Antibodies (“Ngin”) Consortium Agreement
12/34/56